Mela Sciences pulls in funding to fuel reimbursement push for melanoma Dx device

Mela Sciences ($MELA), a New York melanoma diagnostic device company, has raised $27.3 million in new financing to help it win reimbursement and pursue more clinical testing for its MelaFind system, which has U.S. and EU approval to help dermatologists diagnose melanoma. As our sister publication FierceMedicalDevices reported, Mela's shares dropped below the $1 minimum share price a few weeks ago. To maintain its listing, Mela did a one-for-10 reverse stock split, and the new investor financing followed. More

Suggested Articles

InterVene secured $15 million to validate its catheter-based treatment for correcting failed one-way valves in the veins of the legs.

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.